Australian Dry Eye

Click here to edit subtitle

News

view:  full / summary

VIDEO: Novaliq seeks entry into US dry eye market

Posted by australiandryeye on April 17, 2018 at 1:20 AM Comments comments (0)

WASHINGTON ― At the Ophthalmology Innovation Summit at ASCRS here, Bernhard Günther, president of Novaliq, discusses the company’s efforts to enter the U.S. market, principally in treating dry eye disease, by establishing an office in Cambridge, Massachusetts.


https://www.healio.com/ophthalmology/ophthalmic-business/news/online/%7B786f9329-28c4-4580-b18f-94083f661da4%7D/video-novaliq-seeks-entry-into-us-dry-eye-market

SiteOne Therapeutics Announces Abstract Presentation At the Association for Research in Vision and Ophthalmology (ARVO)

Posted by australiandryeye on March 27, 2018 at 6:30 AM Comments comments (1)

BOZEMAN, Montana, March 26, 2018 /PRNewswire/ -- SiteOne Therapeutics, Inc., today announced a presentation at the Association for Research in Vision and Opthalmology (ARVO) meeting in Honolulu, Hawaii, April 29 to May 3, 2018.


The abstract will present preclinical research using SiteOne's novel sodium ion channel blockers showing corneal anesthesia, penetration into the ocular structures, and excellent tolerability after topical administration. The study was conducted to ...

Read Full Post »

Biomedical startup AesculaTech is creating a new, more patient-friendly drug delivery system

Posted by australiandryeye on March 26, 2018 at 8:10 AM Comments comments (0)

“Reverse chocolate” — that’s how AesculaTech co-founder and chief science officer Niki Bayat describes the material created by its proprietary technology. Chocolate is solid until heated, when it melts deliciously into liquid. AesculaTech’s material, on the other hand, is a liquid at low temperatures, turns into a gel when heated and then reaches its final, solid state at body temperature. (If you are having a hard time visualizing the process or are distracted b...

Read Full Post »

Grafton Optical to launch new dry eye products

Posted by australiandryeye on March 26, 2018 at 8:05 AM Comments comments (0)

Grafton Optical will launch SBM Sistemi’s Ocular Surface Analyser and the i-Pen Tear Film Osmolarity System by i-Med Pharma at Optrafair (14–16 April, Birmingham NEC).


The i-Pen is a hand-held electronic device designed to detect and indirectly measure the elevated tear film osmolarity levels associated with dry eye disease.


The in-practice screening device can be used for patients presenting with dry eye symptoms, as well as pre and post-surger...

Read Full Post »

TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease and Supports Successful Clinical Proof-Of-Concept Study with TOP1630

Posted by australiandryeye on March 26, 2018 at 8:05 AM Comments comments (0)

TopiVert Publication Highlights the Potential of Narrow Spectrum Kinase Inhibitors in Dry Eye Disease and Supports Successful Clinical Proof-Of-Concept Study with TOP1630


London, UK, 22 March 2018: TopiVert Pharma Ltd ("TopiVert" or the "Company"), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular and gastrointestinal diseases, today announces the pub...

Read Full Post »

Yuyu to start clinical trials on dry eye treatment

Posted by australiandryeye on March 26, 2018 at 8:05 AM Comments comments (0)


Yuyu Pharmaceuticals said Thursday that it has received approval from the Ministry of Food and Drug Safety to go ahead with domestic phase 1 clinical trials for YY-101, a peptide-based dry eye treatment.


 

Dry eye syndrome is a common eye condition, in which the eye surface gets damaged due to insufficient tear production or excessive tear evaporation. The number of patients suffering from the disorder is on the rise because of the increase of computer...

Read Full Post »

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Posted by australiandryeye on March 26, 2018 at 8:00 AM Comments comments (0)

Reported topline results from two Phase 3 clinical trials of KPI-121 0.25% - STRIDE 1 and STRIDE 2 – in patients with dry eye disease.


Achieved statistical significance for the primary sign endpoint of conjunctival hyperemia at Day 15 in the ITT population in both trials.


Achieved statistical significance for the primary symptom endpoint of ocular discomfort severity at Day 15 in the ITT population in STRIDE 1 with a trend towards a treatment effect i...

Read Full Post »

Eyelove, the sequel: Jennifer Aniston reprises her starring role in Shire's dry eye awareness push

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)


Time for more eyelove, and more Jennifer Aniston. Since the Shire disease awareness campaign launched more than a year ago, the eye community told Shire they wanted more Jen. So the pharma obliged, with original celebrity spokesperson Aniston even more front and center in its just-launched “eyelove” creative.


Aniston kicked off the eyelove campaign in fall 2016 in ads, telling the story of h...

Read Full Post »

Novaliq begins phase 2 dry eye trial of NOV03

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)

The first patient has been enrolled in the SEECASE phase 2 trial of NOV03 for the treatment of dry eye disease, Novaliq announced in a press release.

 

The multicenter, randomized, double-masked, saline-controlled study will evaluate the effect of NOV03 at both twice daily and four times a day.

NOV03 is designed to penetrate further into the meibomian glands, potentially dissolving meibomian lipids and helping to improve gland functionality, the release said.


Read Full Post »

Bausch + Lomb Receives FDA Approval of LUMIFY

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)

The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness


Clinical Studies Showed 95% Symptom Improvement At One Minute, And Reduced Redness For Up To Eight Hours


LAVAL, Quebec, Dec. 22, 2017 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"), today announced that the U.S. Food and Drug Adm...

Read Full Post »

Biotech with treatment for chronic dry eye disease tied to diabetes raises seed capital

Posted by australiandryeye on March 24, 2018 at 8:00 AM Comments comments (0)

Biotech startup Ocunova, a spin-out from the Penn State University College of Medicine, has closed a fresh round of seed funding to support clinical trials for a treatment aimed at a chronic dry eye condition related to diabetes.


The treatment enlists a drug already approved by the FDA to manage alcohol and opioid dependence called Naltrexone. The company noted on its website that more than 3 million diabetic patients experience chronic dry eye in the U.S.


...

Read Full Post »

Aldeyra Therapeutics Inks Collaboration Deal with Johnson & Johnson to Develop Anti-inflammatory Therapies

Posted by australiandryeye on March 24, 2018 at 7:55 AM Comments comments (0)

By Mark Terry


Based in Lexington, Massachusetts, Aldeyra Therapeutics just signed a collaboration research deal with Janssen Research & Development, a Johnson & Johnson company.


The companies will work together to develop drugs that sequester pro-inflammatory aldehyde mediators. This is a new class of therapeutic targets. Aldeyra’s lead program is reproxalap, a first-in-class drug candidate that has shown anti-inflammatory activity in four Pha...

Read Full Post »

Key U.S. Dry Eye Patent Issued to RegeneRx

Posted by australiandryeye on March 24, 2018 at 7:55 AM Comments comments (0)

ROCKVILLE, Md., Feb. 22, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent for Thymosin beta 4 (Tβ4) for use in the treatment of dry eye syndrome. Tβ4 is the active pharmaceutical ingredient in RegeneRx's proprietary drug candidate, RGN-259, a first-in-c...

Read Full Post »

Shire licences Parion dry eye drug in $535m deal

Posted by australiandryeye on March 24, 2018 at 7:50 AM Comments comments (0)

Shire has agreed a licencing deal with Parion Sciences for a dry eye disease drug that bolsters its ophthalmic portfolio, a priority area for the Irish group.


Shire is paying $20m upfront for rights to P-321 a sodium channel (ENaC) inhibitor that is currently heading into a phase II trial, with another near-term development milestone of $20m on the cards in the near future. All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to th...

Read Full Post »

Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome

Posted by australiandryeye on March 24, 2018 at 7:40 AM Comments comments (0)

The pharmaceutical company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational new drug, SYL1001 for the indication of dry eye syndrome. The company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). The company has received final, End-of-Phase II meeting minutes from the FDA.

 

SYL1001 ...

Read Full Post »

Ocugen's dry eye combination product shows positive phase 2 results

Posted by australiandryeye on March 24, 2018 at 7:40 AM Comments comments (0)

 

March 21, 2018

A phase 2 proof-of-concept clinical trial of OCU310, a combination of brimonidine tartrate and loteprednol etabonate, has shown meaningful improvements in patients with dry eye disease, according to an Ocugen press release.

 

Over a 12-week period, the randomized, multicenter, double-masked, placebo-controlled study met its primary endpoint of tolerability, the release said. In addition, it showed meaningful improvements related to dry eye si...

Read Full Post »

A London Biotech Aims to Overtake the Dry Eye Syndrome Market

Posted by australiandryeye on December 12, 2017 at 6:30 PM Comments comments (0)

TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.”


Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently available for patients with this condition.

 

“Most people are just not aware of the huge unmet medical need there is,” to...

Read Full Post »

Azura Ophthalmics receives Series B funding to create treatment for major cause of Dry Eye Disease

Posted by australiandryeye on December 4, 2017 at 10:15 PM Comments comments (0)

Melbourne, October 11, 2017 – Azura Ophthalmics has received US$16 million in Series B funding to develop treatments for Meibomian Gland Dysfunction (MGD) – the number one cause of Dry Eye Disease.


The funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF), TPG Biotech, OrbiMed and Ganot Capital, will allow the Israeli-Australian company to move into its next clinical stage in the development of novel treatments for MGD – an eye...

Read Full Post »

Can cannabis succeed where other compounds have failed

Posted by australiandryeye on November 20, 2017 at 8:15 PM Comments comments (0)

Cannabinoids could have potential in a novel topical drug delivery vehicle to treat neuropathic dry eye pain.


The disconnect between signs and symptoms in dry eye disease is an intriguing clinical problem. Although we know quite a lot about the etiology of dry eye, the ideal structure of the tear film and how to diagnose and treat dry eye disease, there are still some patients who do not respond to treatment or who present complaining of severe symptom...

Read Full Post »

VIDEO: Consider neuropathic pain in stubborn dry eye

Posted by australiandryeye on November 2, 2017 at 6:20 PM Comments comments (0)

CHICAGO – Rich Mangan, OD, and Scott Hauswirth, OD, discussed a new area of ocular surface disease involving chronic, or neuropathic, pain.


Hauswirth said to consider this condition in dry eye patients who experience light sensitivity and those with symptoms that tend to never go away despite treatment.


Read Full Post »

Rss_feed